GlassScriptPhysician profile
Sara Tariq
NPI 1336526763
$955.09
in general payments reported to CMS, 2019-2025
17 companies · $17.93 in 2025
The $17.93 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.93 · 2021: $142 · 2022: $440 · 2023: $218 · 2024: $118 · 2025: $17.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309 · Education: $45.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.53 |
| Education | $45.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $322.09 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $169.39 | 2020-2023 | Opdualag |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2022-2024 | Enhertu |
| Janssen Biotech, INC. | $82.04 | 2022-2024 | Darzalex, Tecvayli |
| Genentech USA, INC. | $55.45 | 2021-2023 | Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $27.30 | 2022 | |
| Abbvie INC. | $22.99 | 2021 | |
| Amgen INC. | $22.49 | 2022 | |
| Celgene Corporation | $21.84 | 2023 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Emd Serono, INC. | $19.49 | 2023 | Tepmetko |
| Kyowa Kirin, INC. | $18.17 | 2022 | |
| Pfizer INC. | $17.93 | 2025 | |
| Rigel Pharmaceuticals, INC. | $17.17 | 2022 | |
| Myovant Sciences INC. | $16.23 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $16.03 | 2023 | Cellsearch |
| Blueprint Medicines Corporation | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Tariq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.